Ashina, Sait
Melo-Carrillo, Agustin
Toluwanimi, Ajayi
Bolo, Nicolas
Szabo, Edina
Borsook, David
Burstein, Rami
Funding for this research was provided by:
Eli Lilly and Company (32939)
Eli Lilly and Company (32939)
Eli Lilly and Company (32939)
Eli Lilly and Company (32939)
Eli Lilly and Company (32939)
Eli Lilly and Company (32939)
Eli Lilly and Company (32939)
Article History
Received: 10 February 2023
Accepted: 3 March 2023
First Online: 16 March 2023
Declarations
:
: All authors have completed the ICMJE uniform disclosure form at (available on request from the corresponding author).S.A. received honoraria for consulting from Allergan/AbbVie, Amgen, Biohaven, Eli Lilly, Impel NeuroPharma, Novartis, Satsuma, Supernus, Theranica, Percept.R.B. is the John Hedley-Whyte Professor of Anesthesia and Neuroscience at the Beth Israel Deaconess Medical Center and Harvard Medical School. He has received research support from the NIH: R01 NS094198-01A1, R37 NS079678, R01NS095655, R01 NS104296, R21 NS106345, Allergan, Teva, Dr. Reddy, Eli Lilly, Trigemina and the Migraine Research Foundation. He is a reviewer for NINDS, holds stock options in AllayLampand Percept; serves as consultant, advisory board member, or has received honoraria from: Alder, Allergan, Amgen, Autonomic Technologies, Avanir, Biohaven, CGRP Diagnostic, Dr. Reddy’s Laboratory, ElectroCore, Eli Lilly, GlaxoSmithKline, Merck, Pernix, Theranica, Teva, and Trigemina. CME fees from Healthlogix, Medlogix, WebMD/Medscape, and Patents 9061025, 11732265.1, 10806890, US2021-0015908, WO21007165, US2021-0128724, WO21005497. DB has served as a consultant for Eli Lilly, Redpin Rx, and Luminous Mind.Other authors declare that they have no competing interests.